Patients with cancer who suffer severe distress are more likely to miss appointments during the course of their radiation therapy and be admitted to the hospital.
Patients with cancer who suffer severe distress are more likely to miss appointments during the course of their radiation therapy (RT) and be admitted to the hospital, according to a study conducted by researchers in the radiation oncology department of Massey Cancer Center in Richmond, Virginia.
Researchers collected distress scores on all patients receiving RT between 2015-2016. Only patients receiving external beam radiotherapy with definitive intent were included in the study, and distress was measured using the NCCN Distress Thermometer and Problem List. Distress scores were separated into 4 categories: severe (7-10), moderate (6-4), low (1-3), and none (0).
Among the 54 patients completing the distress tools, there was a significant association between a severe distress score and both missing at least 1 appointment and having a hospital admission during treatment.
Of patients with severe distress scores, 57% missed at least 1 appointment compared with 18% of those patients with no, low, or moderate distress. Half of patients with severe distress scores were admitted during treatment, while only 11% of patients with no, low, or moderate distress were admitted.
The use of distress tools may help identify patients receiving RT (and perhaps other types of cancer treatment) earlier so that distressing symptoms can be addressed and hospitalization avoided, the researchers wrote.
FDA Approves T-DXd for Previously Treated HER2-Low and -Ultralow Metastatic Breast Cancer
Published: January 27th 2025 | Updated: January 28th 2025T-DXd has received FDA approval for the treatment of unresectable or metastatic HR+, HER2-low/-ultralow breast cancer in patients whose disease progressed on prior endocrine therapy in the metastatic setting.
ctDNA Status May Be Prognostic for DFS With Celecoxib for Stage III Resected Colon Cancer
January 26th 2025While ctDNA positivity was linked to worse overall disease-free survival (DFS) in stage III resected colon cancer, it was associated with significantly improved DFS with celecoxib compared to placebo.